# Metabolic and Inflammatory Parameters According to Chronic Kidney Disease Equations in a Healthy Korean Populations

Jung-ho Shin, M.D., Su Hyun Kim, M.D., Suk-Hee Yu, M.D.

Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea

#### BACKGROUND

- The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation has been recently proposed
- It has been demonstrated by several reports that it estimates glomerular filtration rate (GFR) more accurately than the Modification of Diet in Renal Disease (MDRD) Study equation.
- We investigated the metabolic and inflammatory parameters, and assessed the risk prediction for metabolic syndrome using each equation in a healthy Korean population.

### METHODS

- Data were analyzed from subjects who visited the Health Promotion Center at Chung-Ang University Hospital, Seoul, Korea from January to December in 2010.
- The estimated GFR (eGFR) was calculated using both the abbreviated Modification of Diet in Renal Disease (MDRD) study equation and the Chronic Kidney Disease Epidemiology Collaboration creatinine equation (CKD-EPI).
- The diagnosis of metabolic syndrome (MetS) was made according to the updated guidelines from the American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI)

## **RESULTS**

Table 1. Baseline characteristics

|  | Total (N=3,895) |  |  |
|--|-----------------|--|--|
| Age, years                               | 44.6 ± 10.8     |  |  |
| Female/Male, n                           | 1,853/2,042     |  |  |
| BMI, kg/m <sup>2</sup>                   | 23.2 ± 3.2      |  |  |
| Blood pressure, mmHg                     |                 |  |  |
| Systolic BP                              | 119.5 ± 14.9    |  |  |
| Diastolic BP                             | 71.2 ± 10.3     |  |  |
| Glucose, mg/dl                           | 93.5 ± 18.3     |  |  |
| Triglyceride, mg/dl                      | 107.2 ± 68.5    |  |  |
| HDL cholesterol                          |                 |  |  |
| Female                                   | 56.9 ± 11.7     |  |  |
| Male                                     | 49.1 ± 10.4     |  |  |
| Albumin, g/dl                            | 4.37 ± 0.25     |  |  |
| Uric acid, md/dl                         | 5.07 ± 1.39     |  |  |
| Homocysteine, µmol/l                     | 10.9 ± 4.4      |  |  |
| High-sensitivity CRP, mg/l               | 1.76 ± 4.85     |  |  |
| Estimated GFR, ml/min/1.73m <sup>2</sup> |                 |  |  |
| MDRD                                     | 76.3 ± 11.0     |  |  |
| CKD-EPI                                  | 86.0 ± 13.6     |  |  |
| CKD, n (%)                               |                 |  |  |
| MDRD                                     | 204 (5.2)       |  |  |
| CKD-EPI                                  | 74 (1.9)        |  |  |
| MetS, n (%)                              | 587 (15.1)      |  |  |

• The prevalence of CKD stages 3 to 5 was 5.2% when using the MDRD equation, but was lowered to 1.9% when using the CKD-EPI equation. Then, 3.3% of participants were excluded from CKD by the CKD-EPI equation.

Table 2. Comparison according to estimated GFR equation

|                            | MDRD         | p-value |              | p-value |
|----------------------------|--------------|---------|--------------|---------|
|                            | (n=204)      |         | (n=74)       |         |
| Age, years                 | 54.2 ± 10.8  | <0.001  | 62.8 ± 11.0  | <0.001  |
| Female/Male, n             | 92/112       | 0.473   | 24/50        | 0.009   |
| BMI, kg/m <sup>2</sup>     | 23.8 ± 3.1   | 0.008   | 24.1 ± 3.1   | 0.023   |
| Blood pressure, mmHg       |              |         |              |         |
| Systolic BP                | 121.8 ± 16.4 | 0.027   | 123.8 ± 16.0 | 0.013   |
| Diastolic BP               | 72.9 ± 10.7  | 0.021   | 71.8 ± 10.4  | 0.617   |
| Glucose, mg/dl             | 97.9 ± 21.6  | <0.001  | 106.2 ± 29.2 | <0.001  |
| Triglyceride, mg/dl        | 116.3 ± 71.0 | 0.051   | 130.4 ± 74.2 | 0.003   |
| HDL cholesterol            |              |         |              |         |
| Female                     | 56.7 ± 12.5  | 0.867   | 51.3 ± 12.3  | 0.017   |
| Male                       | 49.4 ± 11.1  | 0.756   | 49.0 ± 11.9  | 0.923   |
| Albumin, g/dl              | 4.36 ± 0.26  | 0.885   | 4.30 ± 0.32  | 0.013   |
| Uric acid, md/dl           | 5.62 ± 1.56  | <0.001  | 6.04 ± 1.78  | <0.001  |
| Homocysteine, µmol/l       | 13.1 ± 4.9   | <0.001  | 13.9 ± 4.9   | <0.001  |
| High-sensitivity CRP, mg/l | 1.90 ± 7.00  | 0.679   | 2.94 ± 11.54 | 0.035   |
| MetS, n (%)                | 45 (22.1)    | 0.006   | 23 (31.1)    | <0.001  |

<sup>\*</sup> P-value was compared with non-CKD population

• We assessed the odds ratio of CKD according to each estimated GFR for MetS by Logistic regression analysis.

Table 3. Odds ratio (OR) for metabolic syndrome

|         | Odds ratio (95% CI) | p-value |
|---------|---------------------|---------|
| MDRD    |                     |         |
| Non-CKD | 1 (Reference)       |         |
| CKD     | 1.64 (1.17 – 2.32)  | 0.005   |
| CKD-EPI |                     |         |
| Non-CKD | 1 (Reference)       |         |
| CKD     | 2.60 (1.58 – 4.30)  | <0.001  |

## CONCLUSIONS

The metabolic and inflammatory parameters tended to deviate more from normal range in participants with CKD when using the CKD-EPI equation and it also assessed the risk of metabolic syndrome more accurately than the MDRD equation.



